<DOC>
	<DOCNO>NCT01301430</DOCNO>
	<brief_summary>Investigation safety , tolerability efficacy H-1 parvovirus ( H-1PV ) subject suffer glioblastoma multiforme .</brief_summary>
	<brief_title>Parvovirus H-1 ( ParvOryx ) Patients With Progressive Primary Recurrent Glioblastoma Multiforme .</brief_title>
	<detailed_description>Investigation safety , tolerability efficacy H-1 parvovirus ( H-1PV ) subject suffer glioblastoma multiforme . H-1PV primarily administer either intratumoral intravenously . Ten day thereafter complete subtotal tumor resection subsequent administration H-1PV wall resection cavity carry .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Age equal 18 year old , Diagnosis glioblastoma multiforme , Written inform consent , Recurrent progressive disease despite previous radio and/or chemotherapy , Indication complete subtotal tumor resection , Life expectancy least 3 month , Consent sample investigation biological specimen , Karnofsky Performance Score equal 60 , Adequate seizure control , Adequate bone marrow function : neutrophil &gt; 1.5 x 10exp9/L , platelet &gt; 100 x 10exp9/L , hemoglobin &gt; 9.0 g/dL , Adequate liver function : Bilirubin &lt; 2.0 g/dL , ASAT , ALAT , AP , GGT &lt; 3 x ULN , Adequate renal function : Creatinine &lt; 1.8 g/dL , Adequate blood clotting : aPTT &lt; 35 sec , INR &lt; 1.2 , Negative serology HIV , HBV HCV , Negative BetaHCG test woman childbearing potential , Commitment use adequate contraception ( gender ) six month study entry , Commitment omit exposure infant &lt; 18 month age immunocompromised individual 28 day first administration IMP . Multifocal disease , Evidence distant tumor metastasis , Contraindications MRI , Active infection within 5 day prior study inclusion , Chemotherapy within 4 week prior study inclusion , Radiotherapy within 6 week prior study inclusion , Participation another interventional trial within last 30 day , Treatment antiangiogenic substance within 21 day prior therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Progressive glioblastoma multiforme</keyword>
	<keyword>Recurrent glioblastoma multiforme</keyword>
	<keyword>Oncolytic virus</keyword>
</DOC>